Pfizer Inc.
Combinations for Treating Cancer
Last updated:
Abstract:
Provided herein are methods and combinations for treating a subject having cancer by administering to the subject a PD-1/PD-L1 axis inhibitor, a CD-122-biased-cytokine agonist, and optionally a PARP inhibitor.
Status:
Application
Type:
Utility
Filling date:
4 Nov 2019
Issue date:
18 Nov 2021